Cardiogenic shock in acute coronary syndrome

Medical Science Monitor

Volumn 15, Issue 3, 2009, Pages

  Ruiz Bailén, Manuel ^a,e   Rucabado Aguilar, Luis ^a   Expósito Ruiz, Manuela ^a   Morante Valle, Antonia ^a   Castillo Rivera, Ana ^a   Pintor Mármol, Antonio ^a   Rosell Ortiz, Fernando ^b   Mellado Vergel, Francisco José ^c   MacHado Casas, Juan ^a   Tejero Pedregosa, Armando ^a   Lara Torrano, Juan ^d  

^a Medical Surgical University Hospital   (Spain)

^b Emergency Care Public Company   (Spain)

^c Hospital Del Toyo   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e 23650 Torredonjimeno ^*  (Spain)

Author keywords

Acute coronary syndrome; Cardiogenic shock; Mortality; Pathophysiology; Percutaneous coronary intervention

Indexed keywords

ALTEPLASE; CATECHOLAMINE; CATECHOLAMINE DERIVATIVE; DOBUTAMINE; DOPAMINE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LEVOSIMENDAN; PLACEBO; RETEPLASE; STREPTOKINASE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; AORTA BALLOON; BLEEDING DISORDER; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CLINICAL TRIAL; CORONARY REPERFUSION; DISEASE SEVERITY; DRUG MECHANISM; ECHOCARDIOGRAPHY; FIBRINOLYSIS; HEART ASSIST DEVICE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; ST SEGMENT ELEVATION; SURVIVAL RATE; SWAN GANZ CATHETER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; PATHOLOGY;

ACUTE CORONARY SYNDROME; HUMANS; MYOCARDIAL INFARCTION; PROGNOSIS; SHOCK, CARDIOGENIC;

EID: 65349084947     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Hochman JS. Cardiogenic Shock complicating acute myocardial infarction. Expanding the paradigm. Circulation, 2003; 107: 2998-3002 (Pubitemid 36758968)
2. Goldberg RJ, Gore JM, Alpert JS et al: Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med, 1991; 325(16): 1117-1122
3. Forrester JS, Diamond G, Chatterjee K, Swan HJ: Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med, 1976; 295: 1404-1413
4. Forrester JS, Diamond G, Chatterjee K, Swan HJ: Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts). N Engl J Med, 1976; 295(24): 1356-1362
5. Holmes DR Jr, Bates ER, Kleiman NS et al: Contemporary reperfu- sion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol, 1995; 26(3): 668-674
6. Holmes DR Jr: Cardiogenic shock: a lethal complication of acute myocardial infarction. Rev Cardiovasc Med, 2003; 4(3): 131-135
7. Webb JG, Sleeper LA, Buller CE et al: Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: A report from the SHOCK Trial Registry. J Am Coll Cardiol, 2000; 36: 1084-1090
8. Menon V, White H, LeJemtel T et al: The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol, 2000; 36(3 Suppl.A): 1071-1076
9. Hasdai D, Holmes DR Jr, Topol EJ et al: Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. Eur Heart J, 1999; 20(2): 128-135
10. Sanborn TA, Feldman T: Management strategies for cardiogenic shock. Curr Opin Cardiol, 2004; 19(6): 608-612
11. Davies CH: Revascularization for cardiogenic shock. QJM, 2001; 94(2): 57-67
12. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med, 1997; 23: 1621-1628
13. Steg PG, Bonnefoy E, Chabaud S et al: Impact of time to treatment on mortality after prehospitalary fibrinolysis or primary angioplasty. Data from the captim randomized clinical trial. Circulation, 2003; 108: 2851-2856
14. Shavelle DM, Rasouli ML, Frederick Pet al; National Registry of Myocardial Infarction Investigators: Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis). Am J Cardiol, 2005; 96(9): 1227-1232
15. Zeller M, Cottin Y, Brindisi MC et al: The RICO survey working group. Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction. Eur Heart J, 2004; 5(4): 308-312
16. Hochman JS, Boland J, Sleeper LA et al: Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation, 1995; 91(3): 873-881
17. Bengtson JR, Kaplan AJ, Pieper KS et al: Prognosis in cardiogenic shock alter acute myocardial infarction in patients without Heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med, 1993; 94: 265-273
18. Hands ME, Rutherford JD, Muller JE et al: The in-hospital development of cardiogenic shock alter myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS study group. J Am Coll Cardiol, 1998; 14: 40-46
19. Leor J, Goldbourt U, Reicher-Reiss H et al: Cardiogenic Shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med, 1993; 94: 265-273 (Pubitemid 23074800)
20. Berger PB, Tuttle RH, Holmes DR Jr et al: One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. Circulation, 1999; 99(7): 873-878 (Pubitemid 29094299)
21. Hasdai D, Califf RM, Thompson TD et al: Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol, 2000; 35(1): 136-143
22. Tudesco JV, Wiliams BA, Wright RS et al: Baseline comorbidities and treatment strategy in elderly patients are associated with outcome of cardiogenic shock in a community-based population. Am Heart J, 2003; 24: 472-478
23. Urban P, Stauffer JC, Bleed D et al: A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J, 1999; 20(14): 1030-1038
24. Dzavik V, Sleeper LA, Cocke TP et al: Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J, 2003; 24(9): 828-837
25. Menon V, Hochman JS, Stebbins A et al: Lack of progress in cardio- genic shock: lessons from the GUSTO trials. Eur Heart J, 2000; 21(23): 1928-1936
26. A comparison of reteplase with alteplase for acute myocardial infarction: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med, 1997; 337(16): 1118-1123
27. The TRAndolapril Cardiac Evaluation (TRACE) study: Rationale, design, and baseline characteristics of the screened population. The Trace Study Group. Am J Cardiol, 1994; 73(10): 44C-50C
28. Babaev A, Frederick PD, Pasta DJ et al: Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA, 2005; 294(4): 448-454
29. Holmes DR Jr, Berger PB, Hochman JS et al: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation, 1999; 100(20): 2067-2073
30. Nordhaug D, Steensrud T, Muller S et al: Intraaortic balloon pumping improves hemodynamics and right ventricular efficiency in acute ischemic right ventricular failure. Ann Thorac Surg, 2004; 78(4): 1426-1432
31. Jacobs AK, Leopold JA, Bates E et al: Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol, 2003; 41(8): 1273-1279
32. Hochman JS, Buller CE, Sleeper LA et al: Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol, 2000; 36(3 Suppl.A): 1063-1070
33. Picard MH, Davidoff R, Sleeper LA et al: SHOCK Trial. SHould we emergently revascularize Occluded Coronaries for Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation, 2003; 107(2): 279-284
34. Hochman JS, Sleeper LA, White HD et al: SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. One-year survival following early revascularization for cardiogenic shock. JAMA, 2001; 285(2): 190-192
35. Bolli R: Why myocardial stunning is clinically important. Basic Res Cardiol, 1998; 93(3): 169-172
36. Jacobs AK, French JK, Col J et al: Cardiogenic shock with non-ST-seg- ment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK? J Am Coll Cardiol, 2000; 36(3 Suppl.A): 1091-1096
37. Prasad A, Lennon RJ, Rihal CS et al: Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J, 2004l 147(6): 1066-1070 (Pubitemid 38880966)
38. Wollert KC, Drexler H: Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world? Circulation, 2002; 106(17): 2164-2166 (Pubitemid 35222205)
39. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001; 357(9266): 1385-1390
40. Hollenberg SM, Kavinsky CJ, Parrillo JE: Cardiogenic Shock. Ann Inter Med, 1999; 131: 47-59
41. Alonso DR, Scheidt S, Post M, Killip T: Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation, 1973; 48(3): 588-596
42. Menon V, Slater JN, White HD et al: Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Medn, 2000; 108(5): 374-380
43. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G et al: Widespread coronary inflammation in unstable angina. N Engl J Med, 2000; 347(1): 5-12
44. Abbate A, Bonanno E, Mauriello A et al: Widespread myocardial inflammation and infarct-related artery patency. Circulation, 2004; 110(1): 46-50
45. Jordan JE, Zhao ZQ Vinten-Johansen J: The role of neutrophils in myocardial ischemiareperfusion injury. Cardiovas Res, 1999; 43: 860-878
46. Ziolo MT, Katoh H, Bers DM: Expresion of inducible nitric oxide synthase depresses p-adrenergic-stimulated calcium release from the sar- coplasmic reticulum in intact ventricular myocytes. Circulation, 2001; 104: 2961-2966
47. Cotter G, Kaluski E, Milo O et al: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J, 2003; 24(14): 1287-1295
48. Granger CB, Mahaffey KW, Weaver WD et al: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation, 2003; 108(10): 1184-1190 (Pubitemid 37099985)
49. Geppert A, Huber K Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Curr Opin Crit Care, 2004; 10: 347-353 (Pubitemid 39313503)
50. Lindmark E, Diderholm E, Wallentin L, Siegbahn A: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease; effects of an early invasive or non-invasive strategy. JAMA, 2001; 288: 2107-2113
51. Merino A, Segura I, Vidal B: Eptifibatide blocks C-reactive protein increase alter coronary angioplasty. J Am Coll Cardiol, 2003; 41: 233
52. Matsumura K, Jeremy RW, Schaper J, Becker LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation, 1998; 97(8): 795-804
53. Reynolds HR, Anand SK, Fox JM et al: Restrictive physiology in cardiogenic shock: observations from echocardiography. Am Heart J, 2006; 151(4): 890.e9-15
54. Pfisterer M: Right ventricular involvement in myocardial infarction and cardiogenic shock. Lancet, 2003; 362(9381): 392-394
55. Kinch JW, Ryan TJ: Right ventricular infarction. N Engl J Med, 1994; 330(17): 1211-1217
56. Bowers TR, O'Neill WW, Grines C et al: Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med, 1998; 338(14): 933-940
57. Mendes LA, Picard MH, Sleeper LA et al: Cardiogenic shock: predictors of outcome based on right and left ventricular size and function at presentation. Coron Artery Dis, 2005; 16(4): 209-215
58. Sanborn TA, Sleeper LA, Webb JG et al: Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol, 2003; 42(8): 1373-1379
59. Hernandez Hernandez F, Hernandez Simon P et al: Elective primary angioplasty in cardiogenic shock: results from a single center Rev Esp Cardiol, 2001; 4(9): 1048-1054
60. Lindholm MG, Kober L, Boesgaard S et al: Trandolapril Cardiac Evaluation study group. Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. Eur Heart J, 2003; 24(3): 258-265
61. Wong CS, Sanborn T, Sleeper LA et al: Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol, 2000; 6(3 Suppl.A): 1077-1083
62. Hasdai D, Harrington RA, Hochman JS et al: Platelet glycoprotein IIb/ IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol, 2000; 36(3): 685-692
63. Goldberg RJ, Gore JM, Thompson CA, Gurwitz JH: Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second national registry of myocardial infarction. Am Heart J, 2001; 141(1): 65-72
64. Hasdai D, Holmes DR Jr, Califf RM et al: Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Am Heart J, 1999; 138(1 Pt 1): 21-31
65. Cheitlin MD, Armstrong WF, Aurigemma GP et al: ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr, 2003; 16(10): 1091-1110
66. Nieminen MS, Bohm M, Cowie MR et al; ESC Committee for Practice Guideline (CPG): Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005; 26(4): 384-416
67. Cohen MG, Kelly RV, Kong DF et al: Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med, 2005; 118(5): 482-488
68. Fincke R, Hochman JS, Lowe AM et al: Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol, 2004; 44(2): 340-48
69. Moshkovitz Y, Kaluski E, Milo O et al: Recent developments in cardiac output determination by bioimpedance: comparison with invasive cardiac output and potential cardiovascular applications. Curr Opin Cardiol, 2004; 19(3): 229-237
70. Harding SE, Brown LA, Wynne DG et al: Mechanisms of beta adrenoceptor desensitisation in the failing human heart. Cardiovasc Res, 1994; 28(10): 1451-1460
71. Alhashemi JA: Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists. Br J Anaesth, 2005; 95(5): 648-650
72. Lehmann A, Lang J, Boldt J et al: Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit, 2004; 10(8): MT89-93
73. Fibrinolytic Therapy Trialists (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 1994; 343: 311-322
74. Grupo Italiano per lo Studio della Streptochinasi nell'infarto miocardio: Effectiveness of intravenous thrombolytic treatment in acute infarction. Lancet, 1986; 13: 397-401
75. The International Study Group: In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet, 1990; 336: 71-75
76. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med, 1993; 329(22): 1615-1622
77. Becker RC: Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J, 1993; 125(3): 919-929 (Pubitemid 23079875)
78. Gurbel PA, Anderson RD, MacCord CS et al: Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. Circulation, 1994; 89(1): 361-365
79. Ohman EM, Califf RM, George BS et al: The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J, 1991; 121(3 Pt 1): 895-901
80. Berkowitz SD, Granger CB, Pieper KS et al: Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation, 1997; 95(11): 2508-2516
81. Stomel RJ, Rasak M, Bates ER: Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital. Chest, 1994; 105(4): 997-1002
82. Kovack PJ, Rasak MA, Bates ER et al: Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J Am Coll Cardiol, 1997; 29(7):1454-1458
83. Barron HV, Pizarda SR, Lomnitz DJ et al: Use of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock. J Am Coll Cardiol, 1999; 31: 135
84. Sanborn TA, Sleeper LA, Bates ER et al: Impact of thrombolysis, intraaortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol, 2000; 36(3 Suppl.A): 1123-1129
85. Ohman ME, Nanas J, Stomel RJ: Thrombolysis and counterpulsation to improve cardiogenic shock (TACTIS): results of a prospective randomized trial. Circulation, 2000; 102: 600-604
86. Ohman EM, Nanas J, Stomel RJ et al: Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis, 2005; 19(1): 33-39
87. Barron HV, Every NR, Parsons LS et al: The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J, 2001; 141(6): 933-939
88. French JK, Feldman HA, Assmann SF et al: Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J, 2003; 146: 804-810 (Pubitemid 37378568)
89. Hudson MP, Granger CB, Stebbins AL: Cardiogenic shock survival and use of intraaortic balloon counterpulsation: results from the GUSTO I and III Trials. Circulation, 1999; 100(Suppl.I): I-370 (abstract)
90. Prewitt RM, Gu S, Schick U, Ducas J: Effect of a mechanical vs a pharmacologic increase in aortic pressure on coronary blood flow and thrombolysis induced by IV administration of a thrombolytic agent. Chest, 1997; 111(2): 449-453
91. Garber PJ, Mathieson AL, Ducas J et al: Thrombolytic therapy in car- diogenic shock: effect of increased aortic pressure and rapid tPA administration. Can J Cardiol, 1995; 11(1): 30-36
92. Carnendran L, Abboud R, Sleeper LA et al: Trends in cardiogenic shock: report from the SHOCK Study. The SHould we emergently re- vascularize Occluded Coronaries for cardiogenic shocK? Eur Heart J, 2001; 22(6): 472-478
93. Li JL, Xue H, Wang BS et al: Effect of prolonged intra-aortic balloon pumping in patients with cardiogenic shock following acute myocardial infarction. Med Sci Monit, 2007; 13(6): CR270-74
94. Antman EM, Anbe DT, Armstrong PW et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol, 2004; 44: 671-719
95. Anderson RD, Ohman EM, Holmes DR Jr et al: Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol, 1997; 30(3): 708-715
96. Kurisu S, Inoue I, Kawagoe T et al: Effect of intraaortic balloon pumping on left ventricular function in patients with persistent ST segment elevation after revascularization for acute myocardial infarction. Circ J, 2003; 67(1): 35-39
97. Garatti A, Colombo T, Russo C et al: Impella recover 100 microaxial left ventricular assist device: the Niguarda experience. Transplant Proc, 2004; 36(3): 623-626
98. Garatti A, Colombo T, Russo C et al: Different applications for left ventricular mechanical support with the Impella Recover 100 microaxial blood pump. J Heart Lung Transplant, 2005; 24(4): 481-485
99. Meyns B, Dens J, Sergeant P et al: Initial experiences with the Impella device in patients with cardiogenic shock - Impella support for cardiogenic shock. Thorac Cardiovasc Surg, 2003; 51(6): 312-317
100. Vlasselaers D, Desmet M, Desmet L et al: Ventricular unloading with a miniature axial flow pump in combination with extracorporeal membrane oxygenation. Intensive Care Med, 2006; 32(2): 329-333
101. Morgan JA, Stewart AS, Lee BJ et al: Role of the Abiomed BVS 5000 device for short-term support and bridge to transplantation. ASAIO J, 2004; 50(4): 360-363
102. Kirklin JK, Holman WL: Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances). Curr Opin Cardiol, 2006; 21(2): 120-126
103. Potapov EV, Loforte A, Weng Y et al: Experience with over 1000 Implanted Ventricular Assist Devices. J Card Surg, 2008; 23(3): 185-194
104. Goldberg RJ, Samad NA, Yarzebski J et al: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med, 1999; 340(15): 1162-1168
105. Edep ME, Brown DL: Effect of early revascularization on mortality from cardiogenic shock complicating acute myocardial infarction in California. Am J Cardiol, 2000; 85(10): 1185-1188
106. Antoniucci D, Valenti R, Santoro GM et al: Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol, 1998; 31(2): 294-300
107. Hochman JS, Sleeper LA, Webb JG et al: Effect of early revascularization on mortality in cardiogenic shock complicating acute myocardial infarction. N Engl J Med, 1999; 625-634
108. Halkin A, Stone GW, Grines CL et al: Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry). Am J Cardiol, 2005; 96(12): 1649-1655
109. Dzavik V, Sleeper LA, Picard MH et al: Outcome of patients aged >or=75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myo- cardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J, 2005; 149(6): 1128-1134 (Pubitemid 40848160)
110. Dauerman HL, Goldberg RJ, Malinski M et al: Outcomes and early re- vascularization for patients >65 years of age with cardiogenic shock. Am J Cardiol, 2001; 87(7): 844-848
111. Buller CE, Sleeper LA, Boland J et al: Cardiogenic shock complicating acute myocardial infarction - etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascu- larize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol, 2000; 36(3 Suppl.A): 1063-1070
112. Dauerman HL, Goldberg RJ, White K et al: Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol, 2002; 90: 838-842
113. Iakobishvili Z, Behar S, Boyko V et al: Does current treatment of cardio- genic shock complicating the acute coronary syndromes comply with guidelines? Am Heart J, 2005; 149(1): 98-103 (Pubitemid 40126496)
114. Hochman JS, Sleeper LA, Webb JG et al: Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA, 2006; 295(21): 2511-2515
115. Klein LW, Shaw RE, Krone RJ et al: Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol, 2005; 96(1): 35-41
116. Dzavik V, Burton JR, Kee C et al: Changing practice patterns in the management of acute myocardial infarction complicated by cardiogenic shock: elderly compared with younger patients. Can J Cardiol, 1998; 14(7): 923-930
117. Koreny M, Karth GD, Geppert A et al: Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med, 2002; 112(2): 115-119
118. Lindholm MG, Boesgaard S, Torp-Pedersen C, Kober L; on behalf of the TRACE registry study group: Diabetes mellitus and cardiogenic shock in acute myocardial infarction. Eur J Heart Fail, 2005; 7(5): 834-839
119. Riese U, Brenner S, Docke WD et al: Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T-cells. Mol Cell Biochem, 2000; 212(1-2): 45-50
120. Nishii M, Inomata T, Takehana H et al: Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol, 2004; 44(6): 1292-1297
121. Kerbaul F, Collart F, Giorgi R et al: Increased plasma levels of pro-brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery. Intensive Care Med, 2004; 30(9): 1799-1806
122. Holmes DR Jr, Califf RM, Van de Werf F et al: Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet, 1997; 349(9045): 75-78
123. Popitean L, Barthez O, Rioufol G et al: Factors affecting the management of outcome in elderly patients with acute myocardial infarction Particularly with regard to reperfusion. Data from the French regional RICO survey. Gerontology, 2005; 51(6): 409-415
124. Zeymer U, Vogt A, Zahn R et al: Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J, 2004; 25(4): 322-328
125. Sutton AG, Finn P, Hall JA et al: Predictors of outcome after percutaneous treatment for cardiogenic shock. Heart, 2005; 91(3): 339-344
126. Chodek A, Angioi M, Fajraoui M et al: Mortality prognostic factors of cardiogenic shock complicating an acute myocardial infarction and treated by percutaneous coronary intervention. Ann Cardiol Angeiol (Paris), 2005; 54(2): 74-79
127. Huang R, Sacks J, Thai H et al: Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention. Catheter Cardiovasc Interv, 2005; 65(1): 25-33
128. Chan AW, Chew DP, Bhatt DL et al: Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol, 2002; 89(2): 132-136